SCHEMBL577226

SCHEMBL577226

C[Si](C)(C)C1COCOC1

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8253543 0.65
SCHEMBL762605 0.65
SCHEMBL17965692 0.63
SCHEMBL4980791 0.62
SCHEMBL12052161 0.62
SCHEMBL13532389 0.62
SCHEMBL12949434 0.61
SCHEMBL17528515 0.60
Ethylene SCHEMBL11844746 0.60
SCHEMBL337298 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016142952-A1 PROCESS FOR PREPARATION OF VILAZODONE AND ITS NOVEL INTERMEDIATES NOSCH LABS PRIVATE LIMITED (IN) 2016-09-15 WO claimed
WO-2025050647-A1 IONIZABLE CATIONIC LIPID COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF 晟迪生物医药(苏州)有限公司 2025-03-13 WO disclosed
CN-117986153-A Ionizable cationic lipid compound, and preparation method and application thereof 晟迪生物医药(苏州)有限公司 2024-05-07 CN disclosed
WO-2016142952-A1 PROCESS FOR PREPARATION OF VILAZODONE AND ITS NOVEL INTERMEDIATES NOSCH LABS PRIVATE LIMITED (IN) 2016-09-15 WO disclosed
US-9035070-B2 Process for the preparation of 1-aryl-pyrazol-3-one intermediates useful in the synthesis of sigma receptors inhibitors Esteve Química, S.A. (ES) 2015-05-19 US disclosed
CN-103038208-B Process for the preparation of 1-aryl-pyrazol-3-one intermediates useful in the synthesis of sigma receptors inhibitors ESTEVE QUIMICA SA 2015-05-06 CN disclosed
EP-2598469-B1 PROCESS FOR THE PREPARATION OF 1-ARYL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTORS INHIBITORS ESTEVE QUÍMICA S A (ES) 2014-07-23 EP disclosed
US-20130184472-A1 Process for the Preparation of 1-ARYL-PYRAZOL-3-ONE Intermediates Useful in the Synthesis of SIGMA Receptors Inhibitors ESTEVE QUIMICA, S.A. (ES) 2013-07-18 US disclosed
EP-2418192-A1 Intermediates for the preparation of 1-aryl-pyrazol-3-one compounds useful as sigma receptors inhibitors Esteve Química, S.A. (ES) 2012-02-15 EP disclosed
US-20110009596-A1 PROCESS FOR THE PREPARATION OF N-PROTECTED-DECYLAMINOETHANAL PLUS CHEMICALS SA (CH) 2011-01-13 US disclosed
WO-2009010296-A2 ANTIBODIES AGAINST 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE AND METABOLITES THEREOF CENTRE DE RECHERCHE PUBLIQUE SANTÉ (LU) 2009-01-22 WO disclosed
EP-2016954-A1 Antibodies against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and metabolites thereof Muller, Claude P. (LU) 2009-01-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184472-A1 Process for the Preparation of 1-ARYL-PYRAZOL-3-ONE Intermediates Useful in the Synthesis of SIGMA Receptors Inhibitors SIGMAR1, OPRK1, OPRM1 TSHR 108/4885
US-20110009596-A1 PROCESS FOR THE PREPARATION OF N-PROTECTED-DECYLAMINOETHANAL PTMA, DNPEP, TET2 TSHR 3441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.